TPST vs. MNOV, ASRT, DERM, ANEB, CUE, LPTX, SLS, CRVS, IFRX, and CARM
Should you be buying Tempest Therapeutics stock or one of its competitors? The main competitors of Tempest Therapeutics include MediciNova (MNOV), Assertio (ASRT), Journey Medical (DERM), Anebulo Pharmaceuticals (ANEB), Cue Biopharma (CUE), Leap Therapeutics (LPTX), SELLAS Life Sciences Group (SLS), Corvus Pharmaceuticals (CRVS), InflaRx (IFRX), and Carisma Therapeutics (CARM). These companies are all part of the "pharmaceutical preparations" industry.
Tempest Therapeutics (NASDAQ:TPST) and MediciNova (NASDAQ:MNOV) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation, risk and community ranking.
In the previous week, MediciNova had 1 more articles in the media than Tempest Therapeutics. MarketBeat recorded 1 mentions for MediciNova and 0 mentions for Tempest Therapeutics. MediciNova's average media sentiment score of 0.59 beat Tempest Therapeutics' score of 0.00 indicating that MediciNova is being referred to more favorably in the news media.
MediciNova received 117 more outperform votes than Tempest Therapeutics when rated by MarketBeat users. However, 63.89% of users gave Tempest Therapeutics an outperform vote while only 52.38% of users gave MediciNova an outperform vote.
MediciNova's return on equity of -13.19% beat Tempest Therapeutics' return on equity.
22.5% of Tempest Therapeutics shares are held by institutional investors. Comparatively, 9.9% of MediciNova shares are held by institutional investors. 5.8% of Tempest Therapeutics shares are held by insiders. Comparatively, 16.9% of MediciNova shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
MediciNova has higher revenue and earnings than Tempest Therapeutics. MediciNova is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.
Tempest Therapeutics has a beta of -1.76, meaning that its share price is 276% less volatile than the S&P 500. Comparatively, MediciNova has a beta of 0.75, meaning that its share price is 25% less volatile than the S&P 500.
Tempest Therapeutics currently has a consensus price target of $22.25, suggesting a potential upside of 550.58%. Given Tempest Therapeutics' higher possible upside, equities research analysts plainly believe Tempest Therapeutics is more favorable than MediciNova.
Summary
MediciNova beats Tempest Therapeutics on 10 of the 15 factors compared between the two stocks.
Get Tempest Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TPST and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TPST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tempest Therapeutics Competitors List
Related Companies and Tools
